89
Participants
Start Date
October 16, 2019
Primary Completion Date
September 21, 2023
Study Completion Date
January 8, 2024
NGM120 30mg
NGM120 30mg Subcutaneous Injection
NGM120 100mg
NGM120 100mg Subcutaneous Injection
NGM120 30mg with Gemcitabine and Abraxane
NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
NGM120 100mg with Gemcitabine and Abraxane
NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
NGM120 100mg Q3W
NGM120 100mg Subcutaneous Injection every 3 weeks
Placebo
Placebo
NGM Clinical Study Site, Philadelphia
NGM Clinical Study Site, Washington D.C.
NGM Clinical Study Site, Baltimore
NGM Clinical Study Site, Charleston
NGM Clinical Study Site, Myrtle Beach
NGM Clinical Study Site, Miami
NGM Clinical Study Site, Nashville
NGM Clinical Study Site, Cincinnati
NGM Clinical Study Site, Milwaukee
NGM Clinical Study Site, Chicago
NGM Clinical Study Site, Dallas
NGM Clinical Study Site, Houston
NGM Clinical Study Site, Aurora
NGM Clinical Study Site, Tucson
NGM Clinical Study Site, Los Angeles
NGM Clinical Study Site, Los Angeles
NGM Clinical Study Site, Santa Monica
NGM Clinical Study Site, San Diego
NGM Clinical Study Site, Seattle
NGM Clinical Study Site, Sacramento
Lead Sponsor
NGM Biopharmaceuticals, Inc
INDUSTRY